Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered once a month that has been approved by the FDA since 2006 for wet AMD.

Analysts at GlobalData think that faricimab and another Roche-developed product will be the main derivers of the market in the coming years. The companion product – Susvimo – is an implantable ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Illumina said on Tuesday activist investor Keith Meister would join the gene-sequencing maker's board and former U.S. Food and Drug Administration Commissioner Scott Gottlieb would take over as ...

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving healthy ones intact. After review by the Data and Safety Monitoring Board, ...